Palmer et al. present interim findings from their clinical trial; they describe the reactogenicity and immunogenicity results of a self-amplifying mRNA SARS-CoV-2 booster vaccine within an older population (≥60 years of age).
- Christine D. Palmer
- Ciaran D. Scallan
- Andrew Ustianowski
